Sugi Predict

Sugi Predict / Compounds / SCHEMBL924926

SCHEMBL924926

SCHEMBL924926

CCOC(=O)N=NC(=O)OCC.[Pb].[Pb]

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.50
▸ LMNA P02545 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ GAA P10253 2/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ MGAM O43451 1/20 0.46
▸ SI P14410 1/20 0.46
▸ MGAM2 Q2M2H8 1/20 0.46
▸ SOAT1 P35610 1/20 0.46
▸ TRPA1 O75762 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ HCAR2 Q8TDS4 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ KMT2A Q03164 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ GLO1 Q04760 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4970 0.97 ALDH1A1 (0.53) ALDH1A1LMNAHSD17B10GAAALOX15
SCHEMBL5189732 0.97 ALDH1A1 (0.53) ALDH1A1LMNAHSD17B10GAAALOX15
SCHEMBL2911 0.97 ALDH1A1 (0.53) ALDH1A1LMNAHSD17B10GAAALOX15
SCHEMBL1363305 0.97 ALDH1A1 (0.53) ALDH1A1LMNAHSD17B10GAAALOX15
Phosphine SCHEMBL29254075 0.94 ALDH1A1 (0.50) ALDH1A1LMNAHSD17B10GAAALOX15
SCHEMBL6985828 0.94 ALDH1A1 (0.50) ALDH1A1LMNAHSD17B10GAAALOX15
SCHEMBL20577920 0.94 ALDH1A1 (0.50) ALDH1A1LMNAHSD17B10GAAALOX15
Bromide SCHEMBL8195693 0.92 ALDH1A1 (0.48) ALDH1A1LMNAHSD17B10GAAALOX15
Butane SCHEMBL2936445 0.92 ALDH1A1 (0.48) ALDH1A1LMNAHSD17B10GAAALOX15
SCHEMBL11769437 0.89 ALDH1A1 (0.46) ALDH1A1LMNAHSD17B10GAAALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2671582-B1 RING-FUSED HETEROCYCLIC DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2016-07-13 — — EP disclosed
EP-2671582-A1 RING-FUSED HETEROCYCLIC DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2013-12-11 — — EP disclosed
EP-1934212-B1 9-AZABICYCLO [3 . 3 . 1]NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS MSD OSS BV (NL) 2013-02-20 — — EP disclosed
US-7868017-B2 9-azabicyclo[3.3.1]nonane derivatives N.V. ORGANON (NL) 2011-01-11 — — US disclosed
EP-1261623-B1 NEW RETINOL DERIVATIVES, THE METHOD OF PREPARATIONS AND THE USES THEREOF CHEBIGEN INC (KR) 2009-11-04 — — EP disclosed
WO-2009125430-A2 IMPROVED PROCESS FOR PRODUCING DARIFENACIN MATRIX LABORATOIRES LIMITED (IN) 2009-10-15 — — WO disclosed
EP-1934212-A1 9-AZABICYCLO [3 . 3 . 1]NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS N.V. Organon (NL) 2008-06-25 — — EP disclosed
US-20070112019-A1 9-Azabicyclo[3.3.1]nonane derivatives N.V. ORGANON (NL) 2007-05-17 — — US disclosed
EP-1261623-A4 NEW RETINOL DERIVATIVES, THE METHOD OF PREPARATIONS AND THE USES THEREOF CHEBIGEN INC (KR) 2007-04-25 — — EP disclosed
WO-2007039563-A1 9-AZABICYCLO [3 . 3 . 1] NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS N.V. ORGANON (NL) 2007-04-12 — — WO disclosed
US-7030265-B2 Retinol derivatives, the method of preparations and the uses thereof CHEBIGEN, INC. (KR) 2006-04-18 — — US disclosed
US-20040023888-A1 Retinol derivatives, the method of preparations and the uses thereof CHEBIGEN INC. (KR) 2004-02-05 — — US disclosed
EP-1261623-A1 NEW RETINOL DERIVATIVES, THE METHOD OF PREPARATIONS AND THE USES THEREOF Chebigen Inc. (KR) 2002-12-04 — — EP disclosed
WO-2002055540-A1 NEW RETINOL DERIVATIVES, THE METHOD OF PREPARATIONS AND THE USES THEREOF CHEBIGEN INC. (KR) 2002-07-18 — — WO disclosed
US-6384061-B1 HYDANTOIN COMPOUNDS REPRESENTED BY FORMULA (I) WHICH SHOWS AN INHIBITORY ACTIVITY AGAINST FARNESYL TRANSFERASE, AND THUS CAN BE USED AS AN ANTI-CANCER AGENT, OR PHARMACEUTICALLY ACCEPTABLE SALTS LG CHEMICAL LTD. (KR) 2002-05-07 — — US disclosed
EP-1000036-A1 HYDANTOIN DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE LG CHEMICAL LIMITED (KR) 2000-05-17 — — EP disclosed
WO-1999005117-A1 HYDANTOIN DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE LG CHEMICAL LTD. (KR) 1999-02-04 — — WO disclosed
WO-1996001262-A1 NOVEL QUINOLINE COMPOUND AND PROCESS FOR PREPARATION THEREOF HANMI PHARMACEUTICAL CO., LTD. (KR) 1996-01-18 — — WO disclosed
EP-0571400-A1 NOVEL QUINOLONE COMPOUNDS AND PROCESSES FOR PREPARATION THEREOF HANMI PHARMACEUTICAL CO.,LTD. (KR) 1993-12-01 — — EP disclosed
WO-1992012155-A1 NOVEL QUINOLONE COMPOUNDS AND PROCESSES FOR PREPARATION THEREOF HANMI PHARMACEUTICAL CO., LTD. (KR) 1992-07-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023888-A1 Retinol derivatives, the method of preparations and the uses thereof RBP4, RBP1, ADH4 ALDH1A1 150/4885LMNA 1975/4885HSD17B10 135/4885
US-20070112019-A1 9-Azabicyclo[3.3.1]nonane derivatives AZI2, TPMT, TET3 ALDH1A1 441/4885LMNA 2623/4885HSD17B10 943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.